Loading...
Loading...
ALKS| Name | Value |
|---|---|
| Revenues | 380.9M |
| Cost of Revenue | 61.5M |
| Gross Profit | 319.4M |
| Operating Expense | 275.6M |
| Operating I/L | 43.8M |
| Other Income/Expense | 3.5M |
| Interest Income | 9.4M |
| Pretax | 47.4M |
| Income Tax Expense | -0.4M |
| Net Income/Loss | 47.8M |
Alkermes plc is a biopharmaceutical company that focuses on researching, developing, and commercializing pharmaceutical products to address unmet medical needs in the United States, Ireland, and internationally. The company's marketed products include treatments for schizophrenia, bipolar I disorder, alcohol and opioid dependence, and multiple sclerosis. Additionally, Alkermes is developing an oral atypical antipsychotic drug candidate for adults with schizophrenia and bipolar I disorder, as well as an engineered fusion protein to expand tumor-killing immune cells. The company generates revenue through the sales of its marketed products and potential future sales of its drug candidates.
